Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-Cov-2 Infection (COVID-BioVac)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,100
- 试验地点
- 1
- 主要终点
- COVID-19 vaccines response
研究概览
简要总结
Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)
详细描述
The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 years
- •Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others
- •Signing of informed consent from January to March 2021
排除标准
- 未提供
结局指标
主要结局
COVID-19 vaccines response
时间窗: from Day 1 of first vaccination up to 1 years after the last vaccination
Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers
次要结局
未报告次要终点
研究者
Ciceri Fabio
Principal Investigator, Professor and Head of Hematology
IRCCS San Raffaele